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ABSTRACT 
Introduction: Transplant volume represents lung transplant (LTx) expertise and predicts 
outcomes, so we sought to determine outcomes related to center volumes in CF. 
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Methods: United Network for Organ Sharing data were queried for CF patients receiving 
bilateral LTx from 2005-2015. Multivariable Cox regression was used to model survival to 1 year 
and long-term (>1 year) survival, conditional on surviving at least 1 year. 
 
Results: 2,025 patients and 67 centers were included in the analysis. The median annual LTx 
volumes were 3 in CF (interquartile range [IQR]: 2, 6), and 17 in non-CF (IQR: 8, 33). 
Multivariable Cox regression in cases with complete data and surviving at least 1 year (n=1,510) 
demonstrated that greater annual CF LTx volume (HR per 10 LTx=0.66; 95% CI: 0.49, 0.89; 
p=0.006) but not greater non-CF LTx volume (HR=1.00; 95% CI: 0.96, 1.05; p=0.844) was 
associated with improved long-term survival in LTx recipients with CF. A Wald interaction test 
confirmed that CF LTx volume was more strongly associated with long-term outcomes than non-
CF LTx volume (p=0.012). Center volume was not associated with 1-year survival. 
 
Conclusions: CF-specific expertise predicted improved long-term outcomes of LTx for CF, 
whereas general LTx expertise was unassociated with CF patients’ survival.  
 
INTRODUCTION 
Lung transplantation (LTx) is a surgical treatment option for end-stage lung disease, including 
cystic fibrosis (CF).1 Center volume of LTx has been used as a measure of center expertise, 
and has been shown to predict improved survival after this procedure.2-4 High-volume centers 
are considered to attain better outcomes of LTx due to greater resource availability, more 
experience with complex care including extracorporeal membrane oxygenation (ECMO), and 
advanced understanding of transplant-related complications and therapeutic interventions.2,5  
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We have recently demonstrated that greater center volume of LTx was positively correlated with 
post-transplant survival specifically among patients diagnosed with CF.6 However, a protective 
effect of increased center volume has paradoxical implications for LTx referral in this population. 
CF is the leading indication for LTx among children referred for this procedure,7 therefore 
accounting for a large share of LTx performed at pediatric centers. These centers tend to have 
lower LTx volume than adult programs,6 but may have greater expertise specific to performing 
LTx in CF patients. Using available registry data, we performed this study to determine whether 
center expertise in CF and non-CF LTx were equally associated with improved outcomes of LTx 
in CF. 
 
METHODS 
The local institutional review board approved analysis of de-identified transplant registry data 
with a waiver of individual consent. Data were obtained from the United Network for Organ 
Sharing (UNOS) registry,8 which includes data on all solid organ transplant candidates and 
recipients in the United States (US).  Patients were selected for analysis if they had been 
diagnosed with CF, received a first-time bilateral LTx between May 2005 and March 2015, and 
were age 12-50 years at transplantation. Forty-three patients age <12 years were excluded due 
to falling below the age cutoff for the lung allocation score [LAS] in the US.  The robustness of 
the primary conclusions of the study to including patients age <12 years at transplantation is 
evaluated in the Supporting Information.  During the period of May 2005 – March 2015, center 
volumes in each calendar year were calculated for LTx in CF patients (including patients not 
meeting criteria listed above), and LTx in all other patients. Centers were classified as adult if 
they had performed >50% of LTx in the overall period May 2005-March 2015 in patients age 
≥18 years. The distributions of annual LTx volumes (CF and non-CF) were summarized across 
center-years using medians, ranges, interquartile ranges (IQR), and histograms. 
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Patient survival in days since LTx was analyzed using multivariable Cox proportional hazards 
regression. Outcomes included 1-year survival and, among patients surviving at least 1 year, 
long-term (>1 year) survival. The 1-year survival analysis included all patients. Potential confounders 
included in multivariable models were recipient and donor gender; recipient and donor age; 
recipient body mass index (BMI), LAS, serum creatinine, forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC), supplemental oxygen requirement (L/min), preoperative 
extracorporeal membrane oxygenation (ECMO), most recent available 6-minute walk distance 
(6MWD), need for mechanical ventilation, time spent on the transplant waiting list, and the year 
LTx was performed. Cases with complete covariate data were included in multivariable 
analyses. 
 
Cox proportional hazards models included continuous measures of center annual CF LTx and 
non-CF LTx volumes (number of transplants per year). Wald interaction tests were used to 
examine whether the coefficients for CF and non-CF LTx volume were equal. In each model, 
the proportional hazards assumption of Cox regression was evaluated using the Grambsch-
Therneau global test. To assess whether the findings were confounded by differences in 
survival between pediatric and adult programs, the multivariable analysis was limited to the 
subsample of CF patients transplanted at adult centers. Data analysis was performed in 
Stata/IC 13.1 (College Station, TX: StataCorp LP) and two-sided P<0.05 were considered 
statistically significant. 
 
RESULTS  
There were 2,025 patients who met inclusion criteria, with patient characteristics summarized in 
Table 1. The cohort included 1,027 (51%) males and 998 (49%) females of mean age 28.7±8.8 
years. There were 715 (35%) deaths during follow-up, of which 228 occurred during the first 
year post-transplant. Additionally, observations from 203 surviving patients were censored prior 
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to the first transplant anniversary. Cases in the analysis represented 67 transplant centers (60 
adult, 7 pediatric) that contributed data over 526 center-years. Forty-five of the centers 
performed lung transplants (not limited to CF patients) as early as 2006 and as late as 2014 
(i.e., the first and last full calendar years in the study period). Of the remaining 22 centers, 7 had 
performed a lung transplant in 2006 or earlier but ceased performing transplants by 2014-2015; 
while 15 performed no lung transplants during the study period prior to 2007. Over the 526 
center-years, the median annual CF LTx volume was 3 (range: 1,22; IQR: 2, 6), while the 
median annual non-CF LTx volume was 17 (range: 0, 136; IQR: 8, 33). Histograms of annual 
CF and non-CF LTx volumes across center-years are presented in Figures 1 and 2, 
respectively. 
 
After excluding patients missing data on covariates, multivariable Cox models were fitted to 
compare associations of annual CF LTx and non-CF LTx center volume with 1-year and long-
term survival. In the multivariable models, annual center volumes were divided by 10, and select 
covariates were similarly re-scaled (where indicated by table footnotes) to enhance the 
interpretability of hazard ratios (HRs) and confidence intervals (CIs). As shown in Table 2, 
neither measure of center volume was associated with 1-year outcomes. Among patients 
surviving at least 1 year, however, the multivariable analysis of long-term survival in Table 3 
found that greater annual CF LTx volumes were associated with improved patient outcomes. 
Specifically, each 10 additional CF LTx performed at a particular center in a given year were 
correlated with 34% (95% CI: 11%, 51%; p=0.006) lower mortality hazard. By contrast, 
centerannual volume of LTx in non-CF patients was not associated with survival in this CF 
cohort (HR=1.00; 95% CI: 0.96, 1.05; p=0.844). A statistically significant Wald interaction test 
(p=0.012) was used to formally reject the null hypothesis that annual CF LTx volume and non-
CF LTx volume had equally strong associations with post-transplant survival. A total of 6% of 
patients (127/2,025) were excluded from multivariate analysis due to missing data. There were 
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no statistically significant differences in center volume or survival outcomes between included 
and excluded patients, suggesting that this exclusion did not bias the multivariate analysis.  The 
findings from this analysis were robust to including patients age <12 years at transplantation 
(Supporting Information). 
 
Repeating this analysis in a subsample of CF patients transplanted at adult centers (Table 4), 
we confirmed that only annual CF LTx volume (HR=0.65; 95% CI: 0.47, 0.88; p=0.006) was 
associated with improved long-term survival, and that there was a statistically significant 
difference in the coefficients of annual CF and non-CF LTx volumes (Wald interaction test 
p=0.014). In both analyses of long-term survival (all patients surviving >1 year, and patients 
surviving >1 year who were transplanted in adult centers), global tests of the proportional 
hazards assumption were statistically non-significant (p=0.624 and p=0.466, respectively), 
suggesting that there was no variation of the center CF LTx volume effect over survival times 
past 1 year. 
 
DISCUSSION 
Recent studies have demonstrated that greater LTx volume is associated with improved patient 
survival, better management of complications, decreased need for re-admission, better 
outcomes for patients with risk factors such as ECMO support, and lower costs.3-6,9 Although 
transplant volume is considered a valid measure of center expertise in LTx, these findings 
based on overall LTx volume should be interpreted cautiously when drawing implications for the 
population of LTx candidates with CF. In the US, patients with CF are disproportionately 
transplanted in pediatric and low-volume centers, so center expertise in LTx for CF may be 
discordant with their ranking according to total center LTx volume. In this study, we demonstrate 
that center annual CF LTx volume, and not annual volume of LTx in non-CF patients, is 
associated with improved survival among adolescents and adults with CF undergoing LTx. 
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Associations between greater transplant volume and improved patient outcomes are well-
established across solid organ transplantation. For example, center-specific transplant volume 
is positively correlated with survival in lung, heart, and liver transplantation.3-6,10-13 In the case of 
LTx, observed benefits of transplantation at a high-volume center have motivated 
recommendations to regionalize the practice of LTx,12 refer patients with end-stage lung disease 
to high-volume LTx centers,13 or transfer LTx candidates requiring ECMO support to high-
volume centers.2 Yet, evidence for the relevance of total center volume is tempered by some 
criticisms and limitations. First, center volume explains little of the variation in LTx outcomes.3 
Second, center volume may influence outcomes only among a subset of patients, such as 
patients requiring ECMO support.2 Third, center volume may not capture all relevant aspects of 
center expertise, such as expertise with specific patient populations. Consistent with these 
insights, we have demonstrated that annual center volume of non-CF LTx (accounting for the 
majority of LTx performed)1 was uncorrelated with survival of LTx recipients diagnosed with CF. 
 
Meanwhile, center volume of CF LTx was associated with improved long-term post-transplant 
outcomes among CF patients, whether considering all CF LTx or specifically the CF LTx 
performed in adult transplant programs. Improved survival at high-volume centers has been 
attributed to greater resource availability and experience with more complex patients that may 
require emergent life support with ECMO, as well as an advanced understanding of transplant-
related complications and optimal therapeutic interventions. In this study, we demonstrate that 
the association between center volume and long-term LTx outcomes appears to be conditional 
on the indication for LTx. Yet, it is unclear which specific practices of LTx programs experienced 
in CF improve outcomes for this specific patient population. These centers may have developed 
specific strategies in the following areas that are favorable to survival in CF LTx: donor and 
procurement techniques; perioperative management of the recipient; postoperative 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
management (including mechanical ventilation and hemodynamic strategies); fluid 
management; administration of medications (e.g., antimicrobials and immunosuppressants); 
and long-term management of nutrition, rehabilitation, infection, acute cellular and antibody-
mediated rejection, chronic lung allograft dysfunction, and CF comorbidities. However, the lack 
of an association between CF LTx volume and early (1-year) outcomes suggests that expertise 
related to perioperative management or management of early LTx complications is unlikely to 
explain the survival advantage attributed to greater center volume in CF LTx.6 Understanding 
changes in practice that develop as centers gain expertise in CF LTx may assist high-volume 
transplant centers without extensive expertise in CF when they perform LTx for this indication. 
 
The current analysis confirms what has been previously reported in the CF population regarding 
older age being associated with improved survival post-LTx.14 Recent analysis of the 
international CF population identified that with onset of the survival difference seems to occur at 
approximately 1 year post-transplant with an interesting caveat that this age-based survival 
disparity was particularly relevant when comparing children and adults transplanted at majority-
adult programs in the US.14 In other parts of the world, especially Europe and Australia, children 
with CF undergo LTx primarily at adult institutions where high overall transplant volume is 
combined with experience in pediatric CF patients, so the current study is reporting on the US 
experience. Since the inception of the LAS in the US, the adult CF population has experienced 
a significant survival benefit.15 In comparison, the adolescent CF group has a higher hazard of 
post-LTx mortality that increases with attained rate with the highest risk being between 16 and 
20 years of age but declines thereafter.16 Although, we cannot identify the causality of this age 
disparity in post-LTx outcomes in CF, it clearly needs further study to improve survival in the 
younger CF population. 
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The central limitation of our analysis is the lack of data on mechanisms explaining how center 
CF LTx volume influences outcomes of CF patients undergoing LTx. Other limitations include 
the lack of important clinical variables relevant in CF. Specifically, data on bacterial or other 
infections were not collected; and some variables (e.g., pre-transplant FEV1 and FVC) had 
incomplete data.  Additionally, we focused on the cohort of adolescent and adult patients with 
CF meeting the age cutoff (12 years) for donor lung allocation according to the LAS.  Of this 
population, only 7% were transplanted in pediatric centers, so there exists a potential for 
referring CF LTx transplant candidates from adult to pediatric centers if the latter are more 
experienced in LTx specifically for CF.  By contrast, among the 43 patients age <12 years at 
transplantation, 36 (84%) were already transplanted in pediatric centers, so the implications of 
the study for the youngest patients with CF requiring LTx are unclear.  Despite these limitations, 
we have presented results that refine the role attributed to LTx center volume in outcomes of 
transplant recipients with CF. With our analysis limited to data from the US, future research 
should consider investigating center-volume influence on outcomes internationally. 
Nevertheless, our finding that only center volume specific to CF is associated with CF LTx 
recipients’ long-term survival underscores the need to identify specific facets of center expertise 
that contribute to improved patient outcomes, and provides evidence against changing 
transplant policy or practice (e.g., referring patients to high-volume centers regardless of their 
indication for LTx) on the basis of center total procedural volume. 
 
FIGURE CAPTIONS 
Figure 1. Histogram of annual cystic fibrosis lung transplant volume (N=526 center-years). 
Figure 2. Histogram of annual non-cystic fibrosis lung transplant volume (N=526 center-years). 
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DISCLAIMER 
The data reported here have been supplied by the United Network for Organ Sharing as the 
contractor for the Organ Procurement and Transplantation Network.  The interpretation and 
reporting of these data are the responsibility of the authors and in no way should be seen as an 
official policy of or interpretation by the OPTN or the US Government. 
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Table 1. Characteristics of cystic fibrosis patients undergoing lung transplantation. 
 
Variable 
Missing 
data N (%) Mean ± SD 
Transplanted at pediatric center 0 144 (7%)  
Post-transplant mortality 0 715 (35%)  
Male recipient 0 1,027 (51%)  
Male donor 0 1,179 (58%)  
ECMO 0 83 (4%)  
Mechanical ventilation 0 218 (11%)  
Recipient age (years)  0  28.7 ± 8.8  
Donor age (years) 0  30.6 ± 13.6 
Year of transplant 0  2010 ± 3 
Serum creatinine (mg/dL) 10  0.7 ± 0.3 
Body mass index (kg/m2) 2  19.4 ± 2.8 
Final lung allocation score 1  47.2 ± 16.8 
FEV1 (% predicted) 69  25.0 ±13.4 
FVC (% predicted) 45  39.0 ± 13.0 
O2 requirement (L/min) 30  4.8 ± 5.0 
Days on waiting list 0  283 ± 496 
6 minute walk distance (m) 36  270 ± 148 
 
SD, standard deviation, ECMO, extracorporeal membrane oxygenation, FEV1, forced expiratory 
volume in 1 second, FVC, forced vital capacity. 
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Table 2. Multivariable Cox proportional hazards models of 1-year patient survival after lung 
transplantation for cystic fibrosis (N=1,898). 
 
Variable HR 95% CI P 
Annual center LTx volumea,b    
  CF 1.09 (0.73, 1.65) 0.666 
  Non-CF 0.98 (0.92, 1.04) 0.540 
Male recipient 1.03 (0.76, 1.40) 0.860 
Male donor 0.93 (0.69, 1.27) 0.656 
ECMO 0.73 (0.31, 1.77) 0.491 
Mechanical ventilation 1.41 (0.83, 2.40) 0.209 
Recipient age (years)a  0.67 (0.55, 0.82) <0.001 
Donor age (years)a 1.11 (1.00, 1.23) 0.057 
Year of transplant 0.96 (0.91, 1.01) 0.102 
Serum creatinine (mg/dL) 1.73 (1.24, 2.43) 0.001 
Body mass index (kg/m2) 0.98 (0.93, 1.04) 0.512 
Final lung allocation score 1.00 (0.88, 1.14) 0.999 
FEV1 (% predicted)a 0.85 (0.71, 1.01) 0.061 
FVC (% predicted)a 1.03 (0.87, 1.20) 0.748 
O2 requirement (L/min) 1.02 (0.99, 1.06) 0.238 
Days on waiting listb 1.02 (0.99, 1.04) 0.224 
6 minute walk distance (m)b 0.89 (0.80, 0.99) 0.033 
a
 Values divided by 10. 
b
 Values divided by 100. 
 
HR, hazard ratio, CI, confidence interval, LTx, lung transplant, CF, cystic fibrosis, ECMO, 
extracorporeal membrane oxygenation, FEV1, forced expiratory volume in 1 second, FVC, 
forced vital capacity. 
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Table 3. Multivariable Cox proportional hazards models of long-term patient survival after lung 
transplantation for cystic fibrosis, among patients surviving at least 1 year (N=1,510). 
 
Variable HR 95% CI P 
Annual center LTx volumea,b    
  CF 0.66 (0.49, 0.89) 0.006 
  Non-CF 1.00 (0.96, 1.05) 0.844 
Male recipient 1.12 (0.91, 1.37) 0.277 
Male donor 0.97 (0.79, 1.19) 0.765 
ECMO 0.65 (0.25, 1.70) 0.383 
Mechanical ventilation 1.54 (1.04, 2.28) 0.031 
Recipient age (years)a  0.63 (0.56, 0.72) <0.001 
Donor age (years)a 1.01 (0.94, 1.08) 0.820 
Year of transplant 1.07 (1.02, 1.12) 0.006 
Serum creatinine (mg/dL) 1.12 (0.85, 1.49) 0.426 
Body mass index (kg/m2) 1.01 (0.97, 1.05) 0.587 
Final lung allocation score 0.95 (0.87, 1.05) 0.324 
FEV1 (% predicted)a 1.01 (0.92, 1.11) 0.857 
FVC (% predicted)a 0.97 (0.87, 1.07) 0.508 
O2 requirement (L/min) 1.00 (0.98, 1.03) 0.791 
Days on waiting listb 0.98 (0.96, 1.00) 0.025 
6 minute walk distance (m)b 0.97 (0.90, 1.04) 0.333 
a
 Values divided by 10. 
b
 Values divided by 100. 
 
HR, hazard ratio, CI, confidence interval, LTx, lung transplant, CF, cystic fibrosis, ECMO, 
extracorporeal membrane oxygenation, FEV1, forced expiratory volume in 1 second, FVC, 
forced vital capacity. 
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Table 4. Multivariable Cox proportional hazards models of long-term patient survival after lung 
transplantation for cystic fibrosis, among patients surviving at least 1 year who received lung 
transplant at majority-adult transplant centers (N=1,399). 
 
Variable HR 95% CI P 
Annual center LTx volumea,b    
  CF 0.65 (0.47, 0.88) 0.006 
  Non-CF 0.99 (0.95, 1.04) 0.729 
Male recipient 1.10 (0.89, 1.36) 0.391 
Male donor 0.92 (0.74, 1.13) 0.428 
ECMO 0.78 (0.30, 2.05) 0.613 
Mechanical ventilation 1.57 (1.06, 2.34) 0.024 
Recipient age (years)a  0.59 (0.52, 0.69) <0.001 
Donor age (years)a 1.00 (0.93, 1.08) 0.948 
Year of transplant 1.08 (1.03, 1.13) 0.003 
Serum creatinine (mg/dL) 1.10 (0.82, 1.48) 0.536 
Body mass index (kg/m2) 1.00 (0.96, 1.04) 0.991 
Final lung allocation score 0.94 (0.85, 1.03) 0.190 
FEV1 (% predicted)a 1.01 (0.91, 1.11) 0.891 
FVC (% predicted)a 0.95 (0.85, 1.05) 0.335 
O2 requirement (L/min) 1.00 (0.97, 1.03) 0.865 
Days on waiting listb 0.98 (0.96, 1.00) 0.067 
6 minute walk distance (m)b 0.95 (0.88, 1.02) 0.166 
a
 Values divided by 10. 
b
 Values divided by 100. 
 
HR, hazard ratio, CI, confidence interval, LTx, lung transplant, CF, cystic fibrosis, ECMO, 
extracorporeal membrane oxygenation, FEV1, forced expiratory volume in 1 second, FVC, 
forced vital capacity. 
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